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Abstract
Background: In addition to androgens, growth factors are also implicated in the development and
neoplastic growth of the prostate gland. Prosaposin is a potent neurotrophic molecule. Homozygous
inactivation of prosaposin in mice has led to the development of a number of abnormalities in the male
reproductive system, including atrophy of the prostate gland and inactivation of mitogen-activated protein
kinase (MAPK) and Akt in prostate epithelial cells.
We have recently reported that prosaposin is expressed at a higher level by androgen-independent (AI)
prostate cancer cells as compared to androgen-sensitive prostate cancer cells or normal prostate epithelial
and stromal cells. In addition, we have demonstrated that a synthetic peptide (prosaptide TX14A), derived
from the trophic sequence of the saposin C domain of prosaposin, stimulated cell proliferation, migration
and invasion and activated the MAPK signaling pathway in prostate cancer cells. The biological significances
of saposin C and prosaposin in prostate cancer are not known.
Results: Here, we report that saposin C, in a cell type-specific and dose-dependent manner, acts as a
survival factor, activates the Akt-signaling pathway, down-modulates caspase-3, -7, and -9 expression and/
or activity, and decreases the cleaved nuclear substrate of caspase-3 in prostate cancer cells under serum-
starvation stress. In addition, prosaptide TX14A, saposin C, or prosaposin decreased the growth-
inhibitory effect, caspase-3/7 activity, and apoptotic cell death induced by etoposide. We also discovered
that saposin C activates the p42/44 MAP kinase pathway in a pertussis toxin-sensitive and
phosphatidylinositol 3-kinase (PI3K) /Akt-dependent manner in prostate cancer cells. Our data also show
that the anti-apoptotic activity of saposin C is at least partially mediated via PI3K/Akt signaling pathway.
Conclusion: We postulate that as a mitogenic, survival, and anti-apoptotic factor for prostate cancer
cells, saposin C or prosaposin may contribute to prostate carcinogenesis at its early androgen-dependent
or metastatic AI state.
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Background
Androgens, growth factors, neuropeptides, and other
trophic agents are involved in normal and neoplastic
growth of the prostate. Prosaposin is the intracellular pre-
cursor of four lysosomal glycoproteins, saposins A-D, that
are involved in lysosomal hydrolysis of sphingolipids.
These saposins, through their interaction with glycosphin-
golipid hydrolases and their substrates, increase lyso-
somal hydrolytic activities. Saposins and prosaposin are
expressed by various cell types and as a secretory protein
in body fluids including blood, seminal plasma, seminif-
erous tubular fluid, and prostatic secretions [1-5]. Prosa-
posin and its active domain, saposin C, are known for
their potent neurotrophic activities and are involved in
neuro-embryological development [6,7]. The neuro-
trophic activity of prosaposin has been attributed to the
NH2-terminal portion of the saposin C domain of the
molecule which is the source for a number of biologically
active synthetic peptides such as prosaptides TX14A [4-6].
Prosaptides (i.e., TX14A), saposin C, and prosaposin exert
their biological effects by binding to a partially character-
ized single high-affinity G-protein coupled receptor
(GPCR) [6-8]. It has been reported that mice with an inac-
tivated prosaposin gene die at 35–40 days of age due to
neurological disorders. These mice also develop several
abnormalities in their reproductive organs, such as atro-
phy and involution of the prostate gland and inactivation
of MAPK and Akt in the prostate epithelium [9,10]. The
spectrum of biological activities of prosaposin or saposin
C in cancer biology in general and in prostate cancer has
not been specifically addressed.
We have recently reported a higher expression of prosa-
posin in androgen-independent (AI) prostate cancer cells
(PC-3 and DU-145) than in androgen-sensitive (AS)
LNCaP or in normal prostate epithelial and stromal cells.
In addition, we have found that prosaptide TX14A stimu-
lates prostate cancer cell proliferation, migration, and
invasion, activates the Raf-MEK-ERK-Elk-1 signaling cas-
cade of the mitogen-activated protein kinase (MAPK)
pathway, and inhibits the growth-inhibitory effects of
sodium selenite administered at apoptogenic concentra-
tions [11].
In the present study, we show for the first time that
saposin C also functions as a survival factor, activates
PI3K/Akt-signaling pathway, and in a cell type-specific
manner, modulates the expression of procaspase- and cas-
pase-3, -7, and -9 in prostate cancer cells under serum-
starvation stress. We demonstrated that prosaptide
TX14A, saposin C, or prosaposin decreased the growth-
inhibitory effects, caspase-3/7 enzymatic activity, and
apoptotic cell death induced by etoposide. In addition,
our data show that saposin C activation of a p42/44
MAPK in prostate cancer cells is not only pertussis toxin-
sensitive, but also PI3K/Akt-dependent. Moreover, the
PI3K-inhibitor, LY294002, restores the apoptogenic effect
of etoposide in prostate cancer cells studied.
We propose that as a survival and anti-apoptotic factor,
saposin C or prosaposin may contribute to prostate car-
cinogenesis or to the development of hormone-refractory
prostate cancer.
Results
Saposin C acts as a survival factor for prostate cancer cells
The effect of saposin C as a survival factor was assessed
under serum-starvation stress. Androgen-sensitive (AS)
LNCaP cells did not maintain their viability when cul-
tured in serum-free, 0.25% FBS-RPMI, or 0.5% FBS-RPMI
media, for more than 36 h. These cells started to detach
from tissue culture plates and cell viability was decreased
to less than 40% as determined by the trypan blue dye-
exclusion method. However, in the presence of 1% FBS,
cells remained attached to the tissue culture plate and
their growth increased 31% at day 4 and 20% on day 6 as
compared with the control values at day 2 (Fig. 1).
Saposin C stimulated proliferation of these cells by 13%
at day 2, 35% at day 4, and 33% at day 6 compared to the
controls. PC-3 cells appeared to be more sensitive to
serum deprivation and the number of live cells decreased
30% by day 4 and 60% by day 6 compared to the control
values at day 2. However, saposin C (at 1.0 nM) increased
cell proliferation by 9% at day 2, 19% at day 4, and 88%
at day 6, compared to control plates at the same time
period. The growth-response of DU-145 cells was differ-
ent from PC-3 or LNCaP cells. In the absence of saposin
C, the number of live cells increased 10% at day 4 and
29% at day 6 compared to day 2. These cells also demon-
strated the highest proliferative response to saposin C at
day 4 by 93% (Fig. 1). Taken together, these data indicate
that saposin C in a dose-dependent and cell type-specific
manner, promotes the survival of the serum-deprived
prostate cancer cells.
Saposin C activates the PI3K/Akt signaling pathway in 
prostate cancer cells
Several studies have demonstrated that the serine/threo-
nine kinase Akt is a pivotal survival effector for prostate
cancer cells and protects them from apoptotic-cell death
induction by various types of stresses. Hence, we next
evaluated the effect of saposin C on the Akt signaling
pathway in cells.
Direct immunoblotting of serum-starved cells for 24 h
showed that saposin C upregulates phosphorylative activ-
ity of Akt at serine 473 in androgen-independent (AI) PC-
3 and DU-145 cells (Fig. 2A). This response was biphasic.
The response of LNCaP cells was distinct and started at 1.0
nM that subsequently returned to a basal level at higherMolecular Cancer 2004, 3:31 http://www.molecular-cancer.com/content/3/1/31
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Saposin C acts as a survival factor for prostate stromal and  cancer cells Figure 1
Saposin C acts as a survival factor for prostate cancer 
cells. Cells were cultured in their complete media for 3 days 
and shifted to their basal (serum-free) media or RPMI-1% FBS 
(only for LNCaP) in the presence or absence of the indicated 
concentrations of saposin C for 2, 4, or 6 days. Tissue cul-
ture media and saposin C were refreshed every 2 days. At 
the end of incubation periods, cells were trypsinized and cell 
number was determined using a hemocytometer and trypan 
blue exclusion method. PC-3 and DU-145 were used as 
androgen-independent and LNCaP cells were used as andro-
gen-sensitive prostate cancer cell lines. Data represent the 
average of three independent experiments in triplicate sam-
ples; bars, ± SEM. * indicates P < 0.05, and ** indicates P < 
0.01 compared to control. Statistical significance was deter-
mined by one-way ANOVA with Bonferroni's corrections.
Saposin C activates Akt signaling pathway in prostate cancer  cells Figure 2
Saposin C activates Akt signaling pathway in prostate 
cancer cells. A, cells were cultured up to 70% confluency in 
their complete media, serum-deprived for 24 h, and treated 
with 10% FBS or saposin C at 0.1, 1, or 10 nM for 10 min. A 
representative culture plate was also treated with LY294002 
(LY; 50 µM) before treating with saposin C (at 1 nM for 
LNCaP and 10 nM for PC-3 and DU-145). Fifteen µg protein 
per sample was subjected to SDS-PAGE under reducing con-
ditions and immunoblotting was carried out using phospho-
specific Akt antibodies against serine 473 or threonine 308. 
B, non-radioactive in vitro kinase assay was performed to 
determine the effect of saposin C on Akt kinase activity as 
described in details in Materials and Methods. Briefly, cells 
were grown as described above and Akt was selectively 
immunoprecipitated from 250 µg protein using 20 µl of 
immobilized Akt 1G1 monoclonal antibody. Immunocom-
plexes were pelletted and resuspended in kinase buffer in the 
presence of 200 µM ATP and 1 µg of Akt/PKB substrate-gly-
cogen synthase kinase fusion protein (GSK-3α/β) and incu-
bated for 30 min at 30°C, allowing immunoprecipitated Akt 
(if activated) to phosphorylate GSK-3. After terminating the 
kinase reaction, phosphorylated GSK-3 was detected by 
SDS-PAGE and immunoblotting using phospho-GSK-3α/β 
antibody. Control loading was evaluated with anti-Akt anti-
body to determine total Akt-level. Each experiment was per-
formed in duplicate, and the assays were repeated three 
times.
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treatment concentrations. Under our experimental condi-
tions, we did not detect any changes in the phosphoryla-
tive activity of Akt at threonine 308. Since Akt is a
downstream effector of PI3K, we tested the effect of the
PI3K-specific inhibitor, LY294002. Pretreatment of cells
with LY294002 (50 µM, 3 h) followed by saposin C treat-
ment substantially reduced phosphorylation levels of
both serine and threonine residues of Akt in AI- and AD-
prostate cancer cells (Fig. 2A).
To determine whether the upregulation of Akt-phosphor-
ylation by saposin C is associated with its kinase activity,
in vitro kinase assays were performed. After 5 or 10 min
exposure of cells to saposin C, activated-Akt induced
phosphorylation of glycogen synthetase kinase-3 (GSK-3;
a well-characterized Akt substrate) in both AS and AI pros-
tate cancer cells (up to 3-fold compared to basal levels) at
concentrations as low as 0.1 nM, was followed by a slight
increase at higher concentrations (Fig. 2B). Using purified
human milk prosaposin, we observed similar responses
(data not shown). The above results indicate that saposin
C activates the Akt-signaling pathway in a PI3K-depend-
ent manner in both AS and AI prostate cancer cells.
Saposin C differentially modulates the expression or 
activity of caspases and PARP in prostate cancer cells 
under serum-starvation stress
An essential component of the programmed death path-
way in many cell types involves proteolytic cleavage of
inactive caspases to catalytically active products. We inves-
tigated the expression of cleaved (active) and non-cleaved
(inactive) forms of the initiator caspase-9, its active down-
stream effectors (caspases-3 and -7), and poly (ADP-
ribose) polymerase (PARP, a nuclear substrate for caspase-
3) in the cells after a 48 h serum deprivation period. Cas-
pase-9 is closely coupled to proapoptotic signals and we
found that the expression of procaspase-9 was not affected
by saposin C; however, we were able to detect a reduction
in its cleaved form at 10 nM saposin C in all cells investi-
gated (Fig. 3).
With respect to the effector caspases, we noticed a dra-
matic dose-dependent increase in the expression of pro-
caspase-3 in the AI PC-3 and DU-145 cell lines. However,
we observed a reduction in expression of caspase-3 in
both AS and AI cancer cells. Furthermore, our data
showed that procaspase-7 expression in these cells was
not affected by saposin C and under our experimental
conditions we did not detect caspase-7 in AI prostate can-
cer cells. In LNCaP cells, we found a reduction in the level
of caspase-7 at 1 or 10 nM of saposin C (Fig. 3). To further
follow the mechanistic response of cells to saposin C in
the death cascade, we examined the expression of one of
the final death substrates, PARP, and its cleaved product.
The intensity of PARP expression was considerably higher
in PC-3 and DU-145 cells than in LNCaP cells. Saposin C,
in a dose-dependent manner, increased PARP expression
and this effect was associated with a parallel dose-depend-
ent reduction of the cleaved (active) PARP levels (Fig. 3).
Interestingly, the ratio of PARP: cleaved PARP expression
in AI PC-3 and DU-145 cells, either at its basal level or
after stimulation with saposin C, was higher than AS
LNCaP cells. In general, saposin C induced a cell type-spe-
cific (AI versus AS) alteration in the expression level of ini-
tiator and effector caspases. This effect suggests a better
survival and anti-apoptotic activity of saposin C in AI
prostate cancer cells than in AS LNCaP cells.
Saposin C protects prostate cancer cells from etoposide-
induced apoptotic cell death
Next, we decided to evaluate the effect of an apoptogenic
agent, etoposide, on cell growth, apoptosis, and caspase
activity in the presence or absence of various effectors.
Cells were treated in complete culture media for three
days, and then subjected to the MTS assay. Using these
experimental conditions, we empirically determined the
lowest concentration of etoposide that would lead to the
highest growth inhibition. We found that the growth
inhibitory effect of etoposide on prostate cancer cells is
also cell type-specific. For example, a 20 µM etoposide
concentration was sufficient to reduce the cell number to
53% in PC-3 and to 58% in LNCaP cells as compared to
their control values. However, DU-145 cells were more
sensitive and treating these cells with only 2 µM etoposide
led to a 69% reduction in the cell number compared to
control values (Fig. 4A). Compared to etoposide-treated
cells, saposin C increased cell growth by 13% in PC-3,
24% in DU-145, and 27% in LNCaP cells. Like saposin C,
prosaposin reduced etoposide-induced growth inhibition
to relatively the same degree. The highest increase in cell
number was achieved with synthetic peptide TX14A
treatment; however treatment of cells with the mutant
769M peptide showed only a negligible effect (2–5%
increase the cell number) (Fig. 4A). These results indicate
that TX14A peptide, saposin C, or prosaposin can reduce
etopside growth-inhibition on prostate cancer cells.
Using the TUNEL assay and above experimental condi-
tions, we next evaluated the effect of saposin C on the per-
centage of apoptotic cells after treating cells with
etoposide for three days. Apoptotic cells were identified as
dense, bright, and punctate, with brownish pigmentation
of poly-fragmented nuclei. Among the three cell lines
investigated, PC-3 proved to be the most resistant cell line
to apoptosis induction by etoposide. Overall, there was a
dose-dependent reduction (with a peak effect at 10 nM) of
apoptotic cells in the three cell lines investigated. Saposin
C decreased apoptotic cells by 47% in PC-3, 89% in DU-
145, and 58% in LNCaP cells (Fig. 4B). This resultMolecular Cancer 2004, 3:31 http://www.molecular-cancer.com/content/3/1/31
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demonstrates the counteracting influence of saposin C
and etoposide on apoptosis in prostate cancer cells.
We also employed a sensitive fluorometric assay to meas-
ure caspase-3/7 (based on DEVDase) activity using the
experimental conditions described above. Saposin C, at 1
nM concentration, demonstrated the highest reduction in
caspase-3/7 activity in AS LNCaP (21%) and in AI PC-3
(35%) and DU-145 cells (30%) (Fig. 5A). Prosaposin-
treated cells also demonstrated a similar effect. TX14A
peptide not only decreased the growth-inhibitory effect of
etoposide (data not shown), but also proved to be a
potent anti-apoptotic peptide, reducing caspase-3/7 activ-
ity by 43% in PC-3, 36% in DU-145, and 30% in LNCaP
cells. However, the control (inactive mutant) peptide's
(769M) effect was minimal (with a 2–5% reduction) (Fig.
5A). These results clearly indicate that the anti-apoptotic
activity of saposin C is at least partially associated with
modulation of caspase-activity.
The PI3K/Akt inhibitor restores apoptogenic activity of 
etoposide in saposin C treated cells
To determine whether or not saposin C anti-etoposide
apoptotic activity is PI3-kinase dependent, the effect of
PI3K/Akt inhibitor (LY294002) on caspase-3/7 activity in
the cells was examined in the presence or absence of
saposin C ± etoposide. Through our initial studies, using
trypan blue exclusion and MTS assays, we found 1.5 µM
of LY294002 was a non-toxic and tolerable dosage for
experimental period (3 days).
Compared to DMSO-treated cells, LY294002 slightly
increased (up to 10%) the caspase-3/7 enzymatic activity
in PC-3 and DU-145 and showed almost no change in
Effect of saposin C on expression/activity of caspases and PARP under serum-starvation stress Figure 3
Effect of saposin C on expression/activity of caspases and PARP under serum-starvation stress. Cells were cul-
tured routinely up to 60% confluency, washed with PBS, and incubated in their respective serum-free media supplemented with 
or without saposin C for 48 h. Cell lysates were prepared as described in Materials and Methods and 75 µg of clarified protein 
samples was subjected to SDS-PAGE under reducing conditions. Western analysis was carried out using monoclonal antibodies 
against non-cleaved and cleaved caspases-3, -7, and -9 and PARP. For control loading, membranes were probed or reprobed 
with anti-actin antibody. Each experiment was performed in duplicate, and the assays were repeated three times.
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Saposin C reduces growth inhibitory effect of etoposide and acts as an anti-apoptotic factor for prostate cancer cells Figure 4
Saposin C reduces growth inhibitory effect of etoposide and acts as an anti-apoptotic factor for prostate can-
cer cells. A, cells were seeded at 2000 per well in 96-well plates in their complete culture media for 3 (for PC-3 and DU-145) 
or 4 days (for LNCaP), treated with vehicle (DMSO), saposin C (0.1, 1, or 10 nM), prosaptide TX14A (10 nM), inactive mutant 
peptide 769M (10 nM), or prosaposin (1 ng/ml) at the indicated concentrations in the presence or absence of etoposide at the 
indicated concentrations for 3 days. After this period cell number was determined using MTS assay and cell type-specific OD/
cell number calibration curve as described in Materials and Methods. B, apoptosis was determined by TUNEL assay. Cells were 
cultured in multiwell chamber slide up to 40% confluency in their complete culture media, and treated with etoposide in the 
presence or absence of saposin C (0.1, 1, or 10 nM) for 3 days. Percentage of apoptosis was determined by random selection 
of 10 microscopic field (at × 200 magnification) and cell count with a hemocytometer. Data expressed at the average of three 
independent experiments and twelve replicate samples; bars, ± SEM. * indicates P < 0.05, and ** indicates P < 0.01 compared to 
control (etoposide). Statistical significance of the effect of saposin C on cell growth and apoptosis was evaluated by one-way 
ANOVA with Bonferroni's corrections. Differences of vehicle (or etoposide)-only treated cells and any other single experi-
mental group of interest (TX14A or prosaposin) was evaluated by Student's t-test and statistical significance was set at P < 0.05.Molecular Cancer 2004, 3:31 http://www.molecular-cancer.com/content/3/1/31
Page 7 of 14
(page number not for citation purposes)
Effects of saposin C on caspase-3/7 activity (A) and the influence of PI3-kinase inhibitor (B) in etoposide-treated cells Figure 5
Effects of saposin C on caspase-3/7 activity (A) and the influence of PI3-kinase inhibitor (B) in etoposide-
treated cells. Cell culture, treatment period, growth and caspase activity was described in Figure 4. Caspase-3/7 activity was 
determined using the Apo-ONE Homoheneous Caspase-3/7 assay kit based on the cleavage of a profluorescent caspase-3/7 
substrate (Z-DEVD-R110) and fluorimetric quantitation was performed at an excitation and emission wavelength of 485+20 
and 535+25 nm, respectively. After correction of the fluorimetric reading with the blank (vehicle control), final fluorescent 
intensity was depicted as an arbitrary endpoint relative fluorescent unit, RFLU. PI3-kinase inhibitor (LY294002; LY) was used at 
final 1.5 µM concentration and saposin C was added at optimal 1 nM (for PC-3 and LNCaP) or 10 nM (for DU-145) concenra-
tion. Etoposide (Et) was added at optimal 20 µM (for PC-3 and LNCaP) or 2 µM (for DU-145). Data expressed are the average 
of three independent experiments and twelve replicate samples; bars, ± SEM. * indicates P < 0.05, and ** indicates P < 0.01. Sta-
tistical significance of the effect of saposin C on cell growth and apoptosis was evaluated by one-way ANOVA with Bonfer-
roni's corrections. Differences of vehicle (or etoposide)-only-treated cells and any other single experimental group of interest 
(TX14A or prosaposin) was evaluated by Student's t-test and statistical significance was set at P < 0.05.Molecular Cancer 2004, 3:31 http://www.molecular-cancer.com/content/3/1/31
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LNCaP (Fig. 5B). As described above, saposin C
significantly decreased induction of caspase-3/7 activity
by etoposide. Saposin C also reduced the induction of
casapases activity by LY294002 under our experimental
conditions. Addition of LY294002 to the cells treated with
saposin C and etoposide increased caspase-3/7 enzymatic
activity, but to a level below than etoposide-only treated
cells (Fig. 5B). These results indicate that antiapoptotic
activity of saposin C and its effect on caspase activity is at
least partially mediated via the PI3K/Akt signaling
pathway.
Saposin C activation of MAPK is pertussis toxin-sensitive 
and PI3K/Akt-dependent
In neuro-glial derived cells, neurotrophic activity, cell-
death protection and the activation of MAPK by prosap-
tides (i.e., TX14A), saposin C, or prosaposin are mediated
by their binding to a pertussis toxin-sensitive GPCR
[6,7,12,13]. Our previous data demonstrated that prostate
cancer cells were differentially responsive to the TX14A
peptide in a number of biofunctional assays [11]. Our
current results indicate the presence of a sensitive and /or
responsive receptor-ligand interaction that could be
accountable for the subsequent activation of downstream
signaling effectors in MAPK- and Akt-signal transduction
pathways. In addition, there is also emerging data indicat-
ing that signaling proteins such as PI3K and Akt can also
activate MAPK pathways [14-16].
We have previously demonstrated MAPK-activation by
the TX14A peptide derived from a trophic sequence of
saposin C [11]. To examine the involvement of GPCR in
saposin C-activation of the Akt-signaling pathway as well
as the possibility of MAPK and Akt cross-signaling initi-
ated by saposin C, we evaluated the effect of saposin C on
p42/44 MAP kinase activation in prostate cancer cells in
the presence or absence of various inhibitors. Treatment
of cells with saposin C increased the phosphorylative
activity of p42/44 MAPK, which was substantially inhib-
ited by pretreating cells with the specific MEK inhibitor
(U0126; Fig. 6). We used 10% FBS treatment as an exter-
nal positive control for induction of p42/44 activity in the
cells. Saposin C treatment of cells pretreated with PT
showed a modest (in LNCaP cells) to strong reduction (in
AI prostate cancer cells) in the level of phospho-p42/44
MAPK. This result clearly indicates a cell type-specific PT-
sensitivity and/or the potential involvement of one or
more G-proteins in saposin C-activation of MAPK path-
way in the cells.
The intensity of reduction of p42/44 activity and its cell
type-specific pattern was very similar to PT plus saposin C-
or PT-treated values. Interestingly, we observed a more
profound reduction in p42/44 phosphorylative activity in
cells pretreated with LY294002 and then treated with
saposin C. To rule out the potential cytotoxic effect of the
inhibitors, viability of cells was also determined by trypan
blue dye-exclusion. We observed essentially similar results
using the other structurally and mechanistically different
PI3-kinase inhibitor (wortmannin). This experiment
revealed that at the end of the pre-treatment incubation
period, cell viability was equal to or more than 95%.
These results indicate that MAPK activation by saposin C
is at least partially mediated by saposin C-regulated PI3K/
Akt pathways in prostate cancer cells. This result also pro-
vides additional proof for simultaneous activation of mul-
tiple (inter-related) signal transduction pathways by
saposin C.
Discussion
Induction of apoptosis by androgen-ablation therapy sig-
nificantly reduces androgen-dependent (AD) prostate
cancer cells, but fails to cure the majority of patients due
to the presence of apoptosis-resistant cancer cells that are
androgen-independent [17]. It is likely that the develop-
ment of these cells is an adaptive response to hormonal
therapy rather the overgrowth of resistant cells. In-depth
understanding of apoptotic phenomena, identification of
its intracellular components, and characterization of its
extracellular effectors as inducers or inhibitors may con-
tribute to therapeutic approaches for prostate cancer.
The  prosaposin  knock-out mouse model has revealed a
number of interesting findings specifically in the male
reproductive organs. Among these are atrophy of the pros-
tate gland, epididymis, and seminal vesicles. Microscopic
evaluation of affected tissues also shows undifferentiated
phenotypes in prostate ventral and dorsal lobules and
atrophy of the tubuloalveolar glands and their epithelial
cell lining [9]. These data are suggestive of a primary role
for prosaposin in development of the prostate gland.
In a variety of neuro-glial derived cells, synthetic peptides
encompassing a trophic sequence of saposin C and/or
prosaposin have been found to induce growth, survival,
and/or differentiation, or to prevent apoptotic cell-death
in vitro and in vivo [11,18-20]. For example, prosaptide-
TX14A and prosaposin, in a dose- and time-dependent
manner reduced apoptotic cell-death induction of pri-
mary Schwann cells cultured in low serum concentrations,
and PI3K inhibitors (wortmannin or LY294002) blocked
their anti-apoptotic effects [21].
Here, we found that under prolonged serum starvation (2
to 6 days), although the responses of androgen-sensitive
(AS) LNCaP and AI PC-3 and DU-145 prostate cancer cells
were different from each other, saposin C in a dose- and
time-dependent manner, proved to increase proliferation
and survival of both cell types (Fig. 1). Normal prostatic
epithelial cells neither tolerated the basal medium norMolecular Cancer 2004, 3:31 http://www.molecular-cancer.com/content/3/1/31
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responded to saposin C (data not shown). Like many
other cancer cells, withdrawal of mitogens, growth factors,
and other trophic factors by serum-starvation, serves as a
potent stimulus and driving force activating different sur-
vival mechanisms that eventually lead to apoptotic cell-
death in AD- and Al-prostate cancer cells [22,23]. Since
the PI3-Kinase/Akt signaling pathway is known as a cen-
tral cell-survival mechanism and an important mediator
of survival signals driven by growth or trophic factors, we
were also interested in examining the level of PI3K/Akt
activity during serum starvation. Interestingly, we found
that saposin C upregulated Akt-p473Ser phosphorylative
activity in the prostate cancer cells under investigation.
This effect was substantially inhibited by LY294002, an
inhibitor of the upstream Akt effector, PI3K (Fig. 2A). In
addition, using an in vitro kinase assay, we proved that
saposin C induction of PI3K/Akt activity in cells was asso-
ciated with increased phosphorylation of GSK3α/β, as a
downstream key target of the Akt kinase (Fig. 2B). Unlike
Akt-p473Ser, our study showed a considerably higher level
of constitutively activated Akt-p308Thr  in all cells and
remained unaffected by saposin C. Other studies have
also supported a central role for the PI3K/Akt pathway as
a dominant growth factor-induced survival pathway for
prostate cancer cells [14,16]. Constitutive activation of the
PI3K/Akt survival pathway has been described as a mech-
anism that enables endocrine-related breast, lung, and
prostate cancer to become refractory to cytotoxic therapy
[24-27]. Interestingly, immunohistochemical analyses
have demonstrated a direct correlation between Akt phos-
phorylation and the Gleason's score in prostate cancer
[28]. Our results provide evidence that implicate the
Saposin C activation of MAPK pathway is pertussis toxin-sensitive and PI3K/Akt-dependent Figure 6
Saposin C activation of MAPK pathway is pertussis toxin-sensitive and PI3K/Akt-dependent. Cells were cultured 
up to 60% confluency in their maintenance media, washed with PBS, serum-deprived for 20 h, and then fresh basal culture 
media was added for an additional 4 h in the presence or absence of LY294002 (50 µM, 3 h), Wortmannin (10 µM, 15 min), 
U0126 (10 µM, 1.5 h), or pertussis toxin (200 ng/ml, 4 h). After pretreatment, saposin C (0.1 nM) was added directly to the 
cells and incubated for 5 min at 37°C. Cell lysates were prepared and 10 µg protein per sample was subjected to SDS-PAGE 
and immunoblotting using phospho-specific p42/44 MAPK antibody. For control loading, membranes were also probed or rep-
robed with p42/44 antibody to detect total p42/44 MAPK. Parallel tissue culture plates, treated in the same manner, were also 
tested for cell viability by trypan blue dye-exclusion assay. FBS at 10% final concentration was used as a positive control. Each 
experiment was performed in duplicate, and the assays were repeated three times.Molecular Cancer 2004, 3:31 http://www.molecular-cancer.com/content/3/1/31
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involvement of PI3K/Akt activity in saposin C (growth
factor)-induced survival of prostate cancer cells.
With respect to prosaposin, immunohistochemical stain-
ing of the involuted and atrophied prostate tissues from
homozygous knock-out mice also showed inactivation of
the MAPK and Akt signaling pathways [9,10]. Apoptotic-
death signal transduction pathways are not limited to
PI3K/Akt and may involve multiple redundant physiolog-
ical pathways. Several studies have shown the involve-
ment of caspases in the apoptosis of the prostate gland in
normal development or malignant conditions [29,30].
For example, immunohistochemical evaluation in
castrated mice and rats showed the presence of (activated)
caspases in prostate and a correlation between caspase-3
expression and the Gleason's grade of tumors [29]. In vitro
studies also revealed that caspase-inhibitory mechanisms
might be involved in metastasis of prostate cancer cells
[15]. We found that saposin C, in a dose-dependent man-
ner, increased procaspase-3 and PARP levels and
decreased the cleaved form of caspase-9 and -3 and PARP
(a caspase-3 substrate) in both AS and AI prostate cancer
cells. PARP cleavage has been recognized as a sensitive
marker of caspase-mediated apoptosis and its cleavage
paralyzes the enzyme's ability to repair DNA strand
breaks. Therefore, reduction of the PARP cleavage is a
strong indicator for anti-apoptotic activity of saposin C.
Although procaspase-7 expression was not affected in any
of the cells investigated, its active form was reduced only
in LNCaP cells and was not detected in AI prostate cancer
cells (Fig. 3). This special pattern for alteration in the level
of procaspase-3, its cleaved form, and PARP was
coincident with saposin C-induced cell survival under
serum-deprivation culture condition (Fig. 1). Such diver-
gent regulation of caspase-3 and PARP has rarely been
reported in prostate cancer cells [31]. However, it has been
demonstrated frequently in the nervous system and there-
fore might represent a unique characteristic of prosaposin
or saposin C as a neurotrophic molecule [32].
Next, we exposed cells to a universal apoptogenic agent,
etoposide, and found that prosaposin or its active deriva-
tives (saposin C or TX14A peptide), were able to decrease
the growth-inhibitory effect of etoposide-treated prostate
cancer cells (Fig. 4). TUNEL assay, as a direct measure of
apoptotic death showed a dose-dependent reduction in
the percentage of apoptotic cells by saposin C (Fig. 4B).
Under similar experimental conditions, we also showed
that saposin C, prosaptide TX14A, or prosaposin reduce
caspase-3/7 activity in cells treated with etoposide. This
effect could be counteracted by administration of a PI3-
kinase inhibitor (LY294002) (Fig. 5A and 5B). These data
are a clear indication that saposin C-inhibition of the
apoptogenic activity of etoposide is at least partially
dependent on the upstream Akt effector, PI3K (Fig. 5B).
Together, the above findings suggest that the two closely
inter-connected cell survival/apoptotic pathways (PI3K/
Akt and caspases) activated by saposin C or prosaposin
might potentially synergize and provide a growth and sur-
vival advantage to both AD- and AI-prostate cancer cells.
Induction of mitogenic, survival, and anti-apoptotic sig-
nals in physiological and pathological conditions may
begin from a wide array of extracellular stimuli and recep-
tors, including receptor tyrosine kinases (RTKs) and G-
protein coupled receptors (GPCRs). From a historical
point of view, considerable attention has been given to
the role of RTKs and their cognate polypeptide ligands in
prostate cancer. However, accumulating evidence support
the involvement of lysophosphatidic acids, neurotrans-
mitters, and neuropeptides such as bombesin and neuro-
tensin through GPCR signaling in the initiation or
progression of prostate cancer [32,33]. GPCRs also use
pathways that are very similar to those utilized by RTKs to
activate survival and anti-apoptotic signaling pathways
such as the prototypic Raf-MEK-MAPK and PI3K/Akt sig-
nal transduction pathways and caspase cascades [32,34-
37].
Here, we showed that saposin C, in a pertussis toxin-sen-
sitive manner, activated p42/44 MAPK (Fig. 6). Our study
demonstrated the involvement of GPCR as a responsible
receptor system interacting with saposin C and therefore
activating the subsequent signaling pathways. Due to the
considerable importance of activation of MAPK signal
transduction activation by saposin C-GPCR and activa-
tion of the Akt signaling pathways, we tested whether
inhibition of PI3K/Akt could affect saposin C-induced
p42/44 MAPK activation. Pretreatment of cells with
LY294002 inhibited saposin C activation of p42/44
MAPK (Fig. 6). These data not only indicate cross-commu-
nication between MAPK- and PI3K/Akt-signaling path-
ways, but also might suggest that simultaneous activation
of the two important signal transduction pathways by
saposin C provide a potent cell survival and apoptotic-
death protection program for prostate cancer cells.
Conclusion
Our data for the first time show that by activation of mul-
tiple inter-related signaling pathways (PI3K/Akt and
MAPK) and cell type-specific modulation of expression or
activity of caspases, saposin C and/or its precursor (prosa-
posin) serve as a survival and anti-apoptotic factor for
both AS- and AI-prostate cancer cells. Elucidation of such
intricate mechanisms could potentially provide a thera-
peutic option that combines cytotoxic therapy and inhibi-
tion of survival/anti-apoptotic signals for AI metastatic
prostate cancer. Finally, our observations provide novel
insights into the diversity of biological activities of prosa-
posin in prostate cancer cells.Molecular Cancer 2004, 3:31 http://www.molecular-cancer.com/content/3/1/31
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Methods
Cell lines
Androgen-independent (PC-3, DU-145) and -sensitive
(LNCaP) prostate cancer cell lines were obtained from the
American Type Culture Collection (Manassas, VA) and
grown in defined media (PC-3 and DU-145 in DMEM-
10% FBS and LNCaP in RPMI-1640-10% FBS supple-
mented with 1 mM sodium pyruvate, 10 mM HEPES).
Purified recombinant human saposin C and prurified
human milk-prosaposin were characterized and provided
by Dr. K. Sandhoff (University of Bonn, Germany) and
Dr. M. Hiraiwa (University of California, San Diego),
respectively.
Cell survival assays
Cells were initially grown in 100 mm plates in their
respective culture media for 3 days, and after washing with
PBS were incubated in serum-free DMEM (PC-3 and DU-
145) or RPMI-1% FBS (LNCaP) in the presence or absence
of saposin C (at 0.1, 1, or 10 nM) for 2, 4, or 6 days.
Saposin C and culture media were replaced every 2 days.
At the end of the incubation periods, cells were
trypsinized and cell number was determined using a
hemocytometer and the trypan blue exclusion method.
Western analysis
Protein expression analysis was performed according to
standard procedures [38]. Briefly, the cell extract was pre-
pared by washing cell monolayers with cold-PBS, lysing
the cells on ice for 15 min with lysis buffer (20 mM PIPES
[pH 7.4], 150 mM NaCl, 1 mM EGTA, 1% Triton X-100,
1.5 mM MgC12) supplemented with a protease inhibitor
cocktail (Roche Diagnostic, Inc., Indianapolis, IN) and 1
mM sodium orthovandate, plus sodium dodecyl sulfate
(SDS) at a final concentration of 0.1%. The lysates were
then centrifuged (15 min, 4°C, 16,000 × g), aliquoted,
and stored at -70°C until use. Protein concentration was
determined by BCA assay (PIERCE, Rockford, IL). Each
experiment was repeated at least two times. For western
analysis, membranes were blocked with 5% BSA in the
rinse buffer (150 mM NaCl, 20 mM Tris, 0.1% Tween 20)
for 1 h, washed in rinse buffer for 10 min, and then incu-
bated with the respective primary antibody at the indi-
cated concentrations (see below). The membranes were
then washed and incubated with the appropriate horse-
radish peroxidase-conjugated secondary antibody
(1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz,
CA) for 1 h at room temperature, washed for 10 min and
four more cycles of 5 min, and treated with an enhanced
chemiluminescence (ECL) detection system (Amersham,
Piscataway, NJ). In some cases, when the signal was very
weak or undetectable, we used ECL-plus (Amersham).
(i) Effect of PI3K/Akt and MEK-inhibitors, or Pertussis Toxin on 
Saposin C Activation of p42/44 MAPK
Cells were grown in their respective complete culture
media for 2–3 days (up to 60% confluency), washed with
PBS, incubated in their serum-free (basal) media for 20 h,
and then fresh basal media was added to all plates for an
additional 4 h. Various inhibitors [LY294002 (50 µM, 3
h), Wortmannin (10 µM, 15 min), U0126 (10 µM, 1.5 h),
and Pertussis toxin (200 ng/ml, 4 h)] were added to the
culture medium, just before treating cells with saposin C
(at 0.1 nM, 5 min). We used 10% FBS as a positive con-
trol. Cells were lysed and 10 µg of clarified protein sam-
ples was subjected to SDS-PAGE under reducing
conditions. Phospho-specific p42/44 antibody (1:1000;
Cell signaling Technologies, Bedford, MA) was used as the
primary antibody and as a loading control. Filters were
also probed or reprobed with anti-p42/44 antibody. Addi-
tional tissue culture plates that had been treated with or
without inhibitors were also tested for cell viability by
trypan blue dye-exclusion assay.
(ii) Saposin C and PI3K/Akt signaling pathway
Cells were cultured up to 70% confluency in their com-
plete media and after washing with PBS, they were serum-
starved for 24 h, and then treated with 10% FBS or saposin
C at 0.1, 1 or 10 nM for 10 min. A representative tissue
culture plate was also pretreated with the PI3K-inhibitor
(LY294002, 50 µM for 3 h) before treating cells with
saposin C (at 1 nM for LNCaP and at 10 nM for PC-3 and
DU-145 cells). After preparation of the cell lysate, 15 µg of
protein per sample was subjected to SDS-PAGE under
reducing conditions. Immunoblotting was performed
using phospho-specific Akt antibodies against serine 473
or threonine 308 (Cell Signaling Technology). A loading
control was evaluated with anti-Akt antibody. Each exper-
iment was performed in duplicate, and the assays were
repeated three times.
Immunoprecipitation and in vitro Akt kinase activity assay
A non-radioactive Akt kinase assay kit (Cell Signaling
Technologies) was used to determine whether saposin C
treatment of cells under serum-starvation stress would
lead to Akt-activation. For Akt-kinase assays, cells were
grown up to 70% confluency in their maintenance media,
serum-starved for 24 h, and then treated for 5 or 10 min
in the presence or absence of saposin C at 0.1, 1, or 10 nM.
Cells were washed once with ice-cold PBS and harvested
under nondenaturing conditions using 1X ice-cold cell
lysis buffer (from the Kit) supplemented with 1 mM phe-
nylmethylsulfonyl fluoride (PMSF) on ice for 5 (or 10)
minutes. Akt was selectively immunoprecipitated from
250 µg protein (whole cell lysates) using 20 µl of immo-
bilized Akt 1G1 monoclonal antibody, and then incu-
bated with gentle rotation for 4 h at 4°C. Samples were
then centrifuged briefly (30 sec, 2000 × g) and pellets wereMolecular Cancer 2004, 3:31 http://www.molecular-cancer.com/content/3/1/31
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washed twice with 1X lysis buffer and once with 1X kinase
buffer. Immunocomplexes (pellets) were resuspended in
40 µl 1X kinase buffer [composed of 25 mM Tris (pH 7.5),
5 mM β-glycerolphosphate, 2 mM DTT, 0.1 mM Na3VO4,
and 10 mM MgC12 supplemented with 200 µM ATP and
1 µg glycogen synthase kinase-3 [GSK-3; a well character-
ized Akt/PKB substrate] of fusion protein (GSK-3α/β) and
incubated 30 minutes at 30°C, allowing immunoprecipi-
tated Akt (if activated) to phosphorylate GSK-3. The
kinase reaction was terminated by adding 20 µl of 3 × SDS
sample buffer. Phosphorylated GSK-3 was then detected
by western analysis using phospho-GSK-3α/β (for Ser 21
of GSK-3α and ser 9 of GSK-3β) antibody. The above in
vitro kinase assay is based on the fact that phosphor-
ylated-Akt (active) regulates GSK-3α/β kinase activity via
phosphorylation at ser 21/9. For control loading, 10 µg
protein per sample from the same whole cell lysates were
subjected to western analysis using monoclonal anti-Akt
antibody or actin. Each experiment was performed in
duplicate, and the assays were repeated three times.
Apoptosis assays
(i) Effect of saposin C on expression of caspases by western analysis
Cells were cultured up to 60% confluency in their com-
plete culture media. After washing with PBS, they were
incubated with their respective serum-free media in the
presence or absence of saposin C at 0.1, 1, or 10 nM for 48
h; whole cell lysates were prepared as described above.
Clarified protein samples (75 µg) were subjected to SDS-
PAGE under reducing conditions. Western analyses were
carried out using monoclonal antibodies against non-
cleaved and cleaved caspases-3, -7, and -9 and poly (ADP-
ribose) polymerase (PARP) provided in an Apoptosis
Sampler Kit (Cell Signaling Technology). Each experiment
was performed in duplicate, and the assays were repeated
three times.
(ii) Fluorometric measurement of caspase-3/7 activity in cells treated 
with etoposide
We next examined the effect of an apoptogenic agent,
etoposide, on cell growth and caspase activity in the pres-
ence or absence of saposin C, prosaposin, prosaptide
TX14A, or an analogous inactive mutant peptide (769M;
4). Cells were seeded at 1,000 per well in 96-well plates in
their complete culture medium for 3 to 4 days. After this
period, cells were treated in complete culture media for 3
days with etoposide (2, 20, or 200 µM) to find the lowest
concentration that led to the highest growth inhibition, as
measured by MTS assay (described above). Using the opti-
mal cell type-specific etoposide concentration (20 µM for
PC-3 and LNCaP and 2 µM for DU-145), cells were treated
with the vehicle (DMSO), saposin C (0.1, 1, 10 nM),
TX14A (10 nM), mutant peptide (769M, 10 nM), or pro-
saposin (at 1 ng/ml). Using the cell type-specific OD/cell
number calibration curve as obtained by MTS assay
(Promega, WI), cell number per well was determined for
the above treatment conditions.
Parallel tissue culture plates were also used to determine
caspase-3/7 activity using the Apo-ONE™ Homogeneous
Caspase-3/7 assay (Promega, WI). This assay provides a
homogeneous Caspase-3/7 reagent (Promega, Technical
Bulletin-TB295) which performs a dual function, by rap-
idly and efficiently permeabilizing the cultured cells and
at the same time exposing the intracellular space to the
profluorescent caspase-3/7 substrate, rhodamine 110 (Z-
DEVD-R110). After cleavage and removal of the DEVD
peptides by caspase-3/7 activity, the fluorescence in each
well was quantitated at an excitation wavelength of 485 +
20 nM and an emission wavelength of 535 + 25 nM and
after correction based on blank control (DMSO-treated
cells at a concentration equal to what used for dissolving
etoposide) or the homogeneous caspase-3/7 reagent.
Final fluorescent intensity was depicted as endpoint rela-
tive fluorescent unit, RFLU.
Using similar experimental conditions but as an inde-
pendent study, the effect of LY294002 (a PI3-kinase
inhibitor) was also evaluated on growth and caspase-3/7
activity of cells treated with saposin C ± etoposide. After
initial studies to find the optimal concentration, we used
a non-toxic tolerable dosage of 1.5 µM for LY294002. In
addition, we chose the most effective (optimal) concen-
tration of etoposide (20 µM for PC-3 and LNCaP and 2
µM for DU-145) and saposin C (1.0 nM for PC-3 and
LNCaP and 10 nM for DU-145) for this study.
(iii) Terminal deoxynucleotide transferase-mediated nick end-labeling 
(TUNEL)
Cells were cultured in multiwell chamber slides and
treated with etoposide in the presence or absence of
saposin C at 0.1, 1, or 10 nM as indicated above. In situ
determination of apoptosis by Terminal dUTP nick-end
labeling (TUNEL) was performed using an ApopTag Per-
oxidase In Situ kit as recommended by the manufacturer
(Chemicon International, Temecula, CA). The ApopTag
Kit detects single- and double-stranded DNA breaks asso-
ciated with apoptosis. Drug-induced DNA damage is not
identified by the TUNEL assay unless it is coupled with the
apoptotic response. Briefly, at the end of the incubation
period, cells were fixed in 1% paraformaldehyde in PBS,
pH 7.4 for 10 min at room temperature, washed with PBS-
twice, and permeabilized in pre-cooled ethanol: acetic
acid (2:1) for 5 min at -20°C. After washing twice in PBS,
5 min each time, endogenous peroxidase activity in the
cells was quenched in 3% H2O2 in PBS for 5 min at room
temperature, incubated with terminal deoxynucleotidyl
transferase (TdT enzyme) and then with peroxidase-con-
jugated anti-digoxigenin antibody. Nuclear staining of the
apoptotic cells was detected by 3',3'-diaminobenzidineMolecular Cancer 2004, 3:31 http://www.molecular-cancer.com/content/3/1/31
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tetrahydrochloride dihydrate substrate, as recommended
by the manufacturer. Cells were then counterstained in
0.5% (w/v) methyl green and slides were mounted under
a glass coverslip in permount mounting medium.
For control staining, the enzyme incubation step was
deleted. Microscopic examination of cells was carried out
using a phase contrast microscope. Cells were counted by
choosing ten random fields and the percentages of apop-
totic cells were determined. Apoptosis was indicated by
the presence of apoptotic bodies, exhibiting brightly
labeled punctuated nuclei.
Statistical analyses
For cell survival and other quantitative data, a one-way
analysis of variance (ANOVA) was employed to evaluate
the influence of one variable on multiple independent
groups. Bonferroni's corrections were also applied when-
ever a significant group effect was observed. To compare a
control group with a single experimental group of interest,
we used the Student's t-test. For cell survival studies, each
treatment concentration was examined three times and in
triplicate samples. The effect of saposin C or other effec-
tors in the presence of etoposide on cell growth, apopto-
sis, or caspase-3/7 activity was studied in twelve replicates
and repeated three times. Statistical significance was set at
p < 0.05 or 0.01. Statistical analyses were performed using
GraphPad Prism version 3.00 for Windows (GraphPad
Software, San Diego, CA).
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